
Emil R Bulatov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8598792/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochemical Journal, 2015, 467, 365-386.	1.7	168
2	The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death and Disease, 2018, 9, 897.	2.7	90
3	Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections. Biomedicines, 2021, 9, 59.	1.4	60
4	Adoptive Immunotherapy beyond CAR T-Cells. Cancers, 2021, 13, 743.	1.7	57
5	Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. Cancers, 2020, 12, 125.	1.7	50
6	Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors. Cell Death Discovery, 2018, 4, 103.	2.0	41
7	Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?. Genes, 2020, 11, 704.	1.0	31
8	Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy. Frontiers in Oncology, 2020, 10, 1460.	1.3	30
9	Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies. Frontiers in Immunology, 2021, 12, 707734.	2.2	30
10	Biophysical Studies on Interactions and Assembly of Full-size E3 Ubiquitin Ligase. Journal of Biological Chemistry, 2015, 290, 4178-4191.	1.6	24
11	Ubiquitin-Proteasome System: Promising Therapeutic Targets in Autoimmune and Neurodegenerative Diseases. BioNanoScience, 2016, 6, 341-344.	1.5	24
12	Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets. Frontiers in Pharmacology, 2018, 9, 450.	1.6	23
13	Knowns and Unknowns about CAR-T Cell Dysfunction. Cancers, 2022, 14, 1078.	1.7	23
14	Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases. Immunology Letters, 2018, 202, 44-51.	1.1	20
15	Novel Isatin-based activator of p53 transcriptional functions in tumor cells. Molecular Biology Research Communications, 2019, 8, 119-128.	0.2	19
16	Effect of size and protein environment on electrochemical properties of gold nanoparticles on carbon electrodes. Bioelectrochemistry, 2009, 77, 37-42.	2.4	18
17	Binding and purification of plasmid DNA using multi-layered carbon nanotubes. Journal of Biotechnology, 2011, 152, 102-107.	1.9	18
18	Novel approaches for the rational design of PROTAC linkers. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 381-390.	0.5	17

EMIL R BULATOV

#	Article	IF	CITATIONS
19	Serendipitous SAD Solution for DMSO-Soaked SOCS2-ElonginC-ElonginB Crystals Using Covalently Incorporated Dimethylarsenic: Insights into Substrate Receptor Conformational Flexibility in Cullin RING Ligases. PLoS ONE, 2015, 10, e0131218.	1.1	16
20	Endonuclease from Gram-Negative Bacteria Serratia marcescens Is as Effective as Pulmozyme in the Hydrolysis of DNA in Sputum. Frontiers in Pharmacology, 2018, 9, 114.	1.6	13
21	Design, synthesis and biological evaluation of 2-quinolyl-1,3-tropolone derivatives as new anti-cancer agents. RSC Advances, 2021, 11, 4555-4571.	1.7	11
22	Granulocyte-Macrophage Colony-Stimulating Factor and CAR-T Technology for Solid Tumors in Experiment. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 115-122.	0.1	2
23	A One-Step Protocol for Chromatographic Purification of Non-recombinant Exogenous Bacterial Enzyme: Nuclease of Serratia marcescens. BioNanoScience, 2016, 6, 335-337.	1.5	1
24	The Effect of Macrophage Polarization on Cytokine Release in CAR-T Antitumor Response. Blood, 2020, 136, 22-22.	0.6	1
25	Expression of mutant p53 affects cancer cell sensitivity to topotecan. Annals of Oncology, 2019, 30, v803.	0.6	0
26	Screening for Immunosuppressive Genes Responsible for Resistance Towards CAR-T Cell Therapy in Cancer Cells. Blood, 2018, 132, 4965-4965.	0.6	0